Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q3 2023
Institutional positions in Aligos Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 36
- −5 vs. Q2 2023
- Shares held
- 25.7M
- −554.6K (−2.1%) vs. Q2 2023
- Total value
- $19.2M
- −$6.30M (−24.7%) vs. Q2 2023
- New holders
- 2
- 3 more added
- Sold out
- 7
- 10 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALGS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.2M |
| Q1 2026 | 35 | $20.6M |
| Q4 2025 | 41 | $26.2M |
| Q3 2025 | 33 | $26.0M |
| Q2 2025 | 37 | $19.5M |
| Q1 2025 | 35 | $27.1M |
| Q4 2024 | 34 | $64.5M |
| Q3 2024 | 27 | $14.7M |
| Q2 2024 | 49 | $16.6M |
| Q1 2024 | 49 | $45.3M |
| Q4 2023 | 40 | $30.1M |
| Q3 2023 | 36 | $19.2M |
| Q2 2023 | 41 | $25.5M |
| Q1 2023 | 46 | $23.9M |
| Q4 2022 | 39 | $25.3M |
| Q3 2022 | 52 | $30.4M |
| Q2 2022 | 60 | $36.0M |
| Q1 2022 | 76 | $68.4M |
| Q4 2021 | 71 | $390.4M |
| Q3 2021 | 68 | $483.9M |
| Q2 2021 | 58 | $550.5M |
| Q1 2021 | 52 | $612.4M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Aligos Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 3,948,360 | $2.95M | 0.10% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,547,030 | $2.65M | 0.33% | 00.0% | Unchanged |
| Tang Capital Management LLC | 3,329,048 | $2.49M | 0.35% | 00.0% | Unchanged |
| Versant Venture Management, LLC | 2,320,381 | $1.73M | 0.92% | 00.0% | Unchanged |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 2,309,764 | $1.73M | 0.04% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 2,076,400 | $1.55M | 0.01% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,223,278 | $913.8K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,150,227 | $859.2K | 0.00% | −718−0.1% | Reduced |
| Vanguard Group Inc | 1,010,617 | $754.9K | 0.00% | +15,905+1.6% | Added |
| Newtyn Management, LLC | 920,000 | $687.2K | 0.17% | +20,000+2.2% | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555.2K | 0.22% | 00.0% | Unchanged |
| Royal Bank of Canada | 644,553 | $481.0K | 0.00% | −195,840−23.3% | Reduced |
| Silverarc Capital Management, LLC | 631,887 | $472.0K | 0.18% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 564,715 | $420.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 321,360 | $240.0K | 0.00% | −109,195−25.4% | Reduced |
| BlackRock Inc. | 296,959 | $221.8K | 0.00% | −3,504−1.2% | Reduced |
| Geode Capital Management, LLC | 241,503 | $180.5K | 0.00% | −15,089−5.9% | Reduced |
| State Street Corp | 97,423 | $72.8K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 92,000 | $68.7K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 91,807 | $68.6K | 0.00% | −84,068−47.8% | Reduced |
| Northern Trust Corp | 39,351 | $29.4K | 0.00% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 31,383 | $23.4K | 0.00% | 00.0% | Unchanged |
| Choate Investment Advisors | 24,000 | $17.9K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 22,924 | $17.1K | 0.00% | −6,259−21.4% | Reduced |
| HarbourVest Partners LLC | 18,783 | $14.0K | 0.00% | 00.0% | Unchanged |
| CWM, LLC | 16,891 | $13.0K | 0.00% | 00.0% | Unchanged |
| Creative Planning | 10,050 | $7.51K | 0.00% | +10,050 | New |
| UBS Group AG | 5,432 | $4.06K | 0.00% | +5,319+4,707.1% | Added |
| Morgan Stanley | 2,000 | $1.49K | 0.00% | −1,000−33.3% | Reduced |
| FMR LLC | 1,200 | $896 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 677 | $506 | 0.00% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 653 | $488 | 0.00% | −970−59.8% | Reduced |
| Wells Fargo & Company | 195 | $146 | 0.00% | −3−1.5% | Reduced |
| ZRC Wealth Management, LLC | 100 | $75 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 37 | $28 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 2 | $1 | 0.00% | +2 | New |
| Deutsche Bank AG | 0 | $0 | 0.00% | −71,290−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −52,400−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −27,859−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −18,353−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −10,105−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −8,000−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1,189−100.0% | Sold out |